Nektar Therapeutics (NKTR) Tops Q3 EPS by 22c
Tweet
Share
E-mailGet Alerts NKTR Hot Sheet
Price: $74.00 -0.71%
Financial Fact:
Cost of goods sold: 7.03M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Cost of goods sold: 7.03M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q3 EPS of $0.39, $0.22 better than the analyst estimate of $0.17. Revenue for the quarter came in at $152.9 million versus the consensus estimate of $114.62 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
- Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
- Marti Technologies (MRT) Misses Q2 EPS by 9c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
